Latest Price Targets from the World's Best Analysts & Research Firms

Analyst & Firm Stock Price Price Target Upside
Downside
Rating Date
K
11626
Keybanc
Sophie Karp
ENPH icon
Enphase Energy
ENPH
$4.91B
$37.53 $31
17%
downside
Underweight 17 Jun ‘25
2 months ago
B
11627
Barclays
Tom O'Malley
NVDA icon
NVIDIA
NVDA
$4.35T
$178.75 $200
12%
upside
Overweight 17 Jun ‘25
2 months ago
JR
11628
Johnson Rice
Martin Malloy
VG
Venture Global, Inc.
VG
$32.7B
$13.48 $20
48%
upside
Buy 17 Jun ‘25
2 months ago
JM
11629
JP Morgan
James Gordon
GRFS icon
Grifois
GRFS
$6.76B
$9.93 $10.30
4%
upside
Neutral 17 Jun ‘25
2 months ago
JM
11630
JP Morgan
Anthony Paolone
AVB icon
AvalonBay Communities
AVB
$27.6B
$193.84 $249
28%
upside
Overweight 17 Jun ‘25
2 months ago
JM
11631
JP Morgan
Anthony Paolone
CPT icon
Camden Property Trust
CPT
$11.8B
$110.64 $129
17%
upside
Underweight 17 Jun ‘25
2 months ago
JM
11632
JP Morgan
Bennett Moore
CRS icon
Carpenter Technology
CRS
$12.3B
$247.29 $305
23%
upside
Overweight 17 Jun ‘25
2 months ago
B
11633
Barclays
George Wang
JBL icon
Jabil
JBL
$23B
$214.73 $223
4%
upside
Overweight 17 Jun ‘25
2 months ago
DD
11634
DA Davidson
Michael Shlisky
MEC icon
Mayville Engineering Co
MEC
$294M
$14.46 $23
59%
upside
Buy 17 Jun ‘25
2 months ago
HW&C
11635
HC Wainwright & Co.
Joseph Pantginis
ESPR icon
Esperion Therapeutics
ESPR
$508M
$2.52 $16
535%
upside
Buy 17 Jun ‘25
2 months ago
U
11636
UBS
Ashwani Verma
ALKS icon
Alkermes
ALKS
$4.43B
$26.85 $42
56%
upside
Buy 17 Jun ‘25
2 months ago
C
11637
Citigroup
Geoff Meacham
PTGX icon
Protagonist Therapeutics
PTGX
$3.58B
$57.47 $72
25%
upside
Buy 17 Jun ‘25
2 months ago
C
11638
Citigroup
Geoff Meacham
NAMS icon
NewAmsterdam Pharma
NAMS
$2.95B
$26.18 $42
60%
upside
Buy 17 Jun ‘25
2 months ago
C
11639
Citigroup
Geoff Meacham
ACLX icon
Arcellx
ACLX
$3.95B
$71.28 $110
54%
upside
Buy 17 Jun ‘25
2 months ago
C
11640
Citigroup
Geoff Meacham
AMLX icon
Amylyx Pharmaceuticals
AMLX
$1.07B
$11.97 $12
0%
upside
Buy 17 Jun ‘25
2 months ago
GR
11641
GLJ Research
Gordon Johnson
SEDG icon
SolarEdge
SEDG
$1.76B
$29.63 $6.90
77%
downside
Sell 17 Jun ‘25
2 months ago
C
11642
Citigroup
Geoff Meacham
ABOS icon
Acumen Pharmaceuticals
ABOS
$84.8M
$1.40 $4
186%
upside
Buy 17 Jun ‘25
2 months ago
N
11643
Needham
Laura Martin
DV icon
DoubleVerify
DV
$2.25B
$13.73 $18
31%
upside
Buy 17 Jun ‘25
2 months ago
C
11644
Citigroup
Geoff Meacham
NVAX icon
Novavax
NVAX
$1.29B
$7.95 $6
25%
downside
Sell 17 Jun ‘25
2 months ago
HW&C
11645
HC Wainwright & Co.
Joseph Pantginis
GALT icon
Galectin Therapeutics
GALT
$317M
$4.95 $6
21%
upside
Buy 17 Jun ‘25
2 months ago
LC
11646
Loop Capital
Alan Gould
ROKU icon
Roku
ROKU
$13.7B
$93.11 $100
7%
upside
Buy 17 Jun ‘25
2 months ago
HW&C
11647
HC Wainwright & Co.
Joseph Pantginis
BLRX
BioLineRX
BLRX
$16.1M
$3.78 $26
588%
upside
Buy 17 Jun ‘25
2 months ago
N
11648
Needham
John Todaro
RIOT icon
Riot Platforms
RIOT
$5.83B
$15.78 $15
5%
downside
Buy 17 Jun ‘25
2 months ago
JM
11649
JP Morgan
Anthony Paolone
FVR
FrontView REIT, Inc.
FVR
$275M
$13.44 $12
11%
downside
Neutral 17 Jun ‘25
2 months ago
JT
11650
Jones Trading
Debanjana Chatterjee
TBPH icon
Theravance Biopharma
TBPH
$687M
$13.65 $24
76%
upside
Buy 17 Jun ‘25
2 months ago